Carisma Therapeutics News

The Analyst Verdict: CARISMA Therapeutics In The Eyes Of 4 Experts

In the preceding three months, 4 analysts have released ratings for CARISMA Therapeutics (NASDAQ:CARM), presenting a wide array of perspectives from bullish to bearish.The table below provides a snaps

BenzingaMay 17 23:01

Carisma Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Carisma Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow JonesMay 17 22:36

HC Wainwright & Co. Reiterates Buy on CARISMA Therapeutics, Maintains $8 Price Target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates CARISMA Therapeutics (NASDAQ:CARM) with a Buy and maintains $8 price target.

BenzingaMay 17 22:25

Buy Rating Affirmed for Carisma Therapeutics Amid Progress in CAR-Monocyte Cancer Therapy

TipRanksMay 17 18:19

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...

PR NewswireMay 16 19:30

Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)

TipRanksMay 14 19:40

Is There An Opportunity With Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 46% Undervaluation?

Yahoo FinanceMay 14 18:31

Carisma Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Carisma Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMay 10 19:56

Carisma Therapeutics Price Target Cut to $8.00/Share From $9.00 by HC Wainwright & Co.

Carisma Therapeutics Price Target Cut to $8.00/Share From $9.00 by HC Wainwright & Co.

Dow JonesMay 10 19:56

HC Wainwright & Co. Maintains Buy on CARISMA Therapeutics, Lowers Price Target to $8

HC Wainwright & Co. analyst Mitchell Kapoor maintains CARISMA Therapeutics with a Buy and lowers the price target from $9 to $8.

Analyst UpgradesMay 10 19:46

CARISMA Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 429.8% HC Wainwright & Co. $9 → $8 Maintains Buy 04/11/2024 297.35% BTIG → $6 Initiates Coverag

BenzingaMay 10 19:45

Buy Rating Affirmed for Carisma Therapeutics Amid Promising Cancer Treatment Developments

TipRanksMay 10 18:48

Securing Success: The Crucial Role of IP Rights in Carisma Therapeutics' Market Dominance

TipRanksMay 10 14:02

Buy Rating for Carisma Therapeutics: Innovative CAR-M Therapies Poised for Market Growth

TipRanksMay 10 07:45

Carisma Therapeutics | 10-Q: Quarterly report

Futu NewsMay 9 19:57 · Announcements

Carisma Therapeutics Says Cash And Equivalents Of $56.5M Expected To Fund Company Into Q3 Of 2025

Carisma Therapeutics Says Cash And Equivalents Of $56.5M Expected To Fund Company Into Q3 Of 2025

BenzingaMay 9 19:50

CARISMA Therapeutics Q1 2024 GAAP EPS $(0.46) Misses $(0.43) Estimate

CARISMA Therapeutics (NASDAQ:CARM) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.43) by 6.98 percent.

BenzingaMay 9 19:49

Carisma Therapeutics 1Q Loss/Shr 46c >CARM

Carisma Therapeutics 1Q Loss/Shr 46c >CARM

Dow JonesMay 9 19:34

Carisma Therapeutics 1Q Rev $3.4M >CARM

Carisma Therapeutics 1Q Rev $3.4M >CARM

Dow JonesMay 9 19:34

Press Release: Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights PR Newswire PHILADELPHIA, May 9, 2024 Announced CT-0525 as lead product candidate for anti-HER2 prog

Dow JonesMay 9 19:30